Evidence map›Paper›PMID 31169922›Full record

ArticleThe Laryngoscope2020

Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.

Juliëtta H C Schuering, Bas J Heijnen, Elisabeth V Sjögren, Antonius P M Langeveld

Abstract readComparative Study
In one paragraph

Article in The Laryngoscope, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Spasmodic Dysphonia.World journal of otorhinolaryngology - head and neck surgery · 2025
    Review
  2. Laryngeal dystonia and vocal tremor response to botulinum toxin injection.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  3. Treatment of relapsing functional and organic dysphonia: a narrative literature review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Juliëtta H C SchueringDepartment of Otolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-9260-6856
Bas J HeijnenDepartment of Otolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-8309-8773
Elisabeth V SjögrenDepartment of Otolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Antonius P M LangeveldDepartment of Otolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives/hypothesisThe current gold standard of therapy for adductor spasmodic dysphonia (AdSD) is injection of botulinum toxin A (BTX) in the adductor musculature. A surgical procedure could potentially offer more stable and long-lasting voice quality. In this study, we report the long-term results of endoscopic laser thyroarytenoid (TA) myoneurectomy versus BTX treatment in the same patients with AdSD. STUDY

designRetrospective case series.

methodsBetween July 2013 and September 2016, a total of 22 patients with AdSD were included. Voice outcomes were measured using the Voice Handicap Index and a Likert-scale patient-reported voice questionnaire. Data were obtained for each patient at four time points: preoperatively with and without BTX and twice postoperatively at 3 months (short term) and 12 months (long term).

resultsNo statistically significant differences were found between voice outcome after BTX injection and the short- and long-term postoperative voice outcomes for the group as a whole. During postoperative follow-up, 10 of the 22 patients (45%) needed a second procedure after an average of 18 months (interquartile range, 13-22 months) due to recurrence of their original voice problem.

conclusionsThe TA myoneurectomy showed encouraging results, comparable to BTX after follow-up of 12 months for the group as a whole. However, after good results initially, voice deterioration was seen in 45% of the patients who all underwent a second procedure. These preliminary results provide important insights into the value of TA myoneurectomy as a potential definite treatment for a select group of patients with AdSD. Further research might explore long-term results after revision surgery. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:741-746, 2020.

Indexed as

Laser TherapyAdultAgedBotulinum Toxins, Type ADysphoniaFemaleHumansInjectionsLaryngeal MusclesMaleMiddle AgedNeuromuscular AgentsPatient Reported Outcome MeasuresRetrospective StudiesTime FactorsTreatment OutcomeBotulinum Toxins, Type ANeuromuscular AgentsAdductor spasmodic dysphoniabotulinum toxinthyroarytenoid myoneurectomy

Identifiers

PMID31169922
PMCPMC7065196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.